SEC ownership of INTERPACE BIOSCIENCES, INC.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001054102.

Comparable stake leader

Douglas M. Singer

Disclosed value leader

Ampersand 2018 Limited Partnership

Comparable rows

1/9

Latest evidence

20 Aug 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
1 of 9
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
Douglas M. Singer
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
20 Aug 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001054102
Issuer location
Parsippany, NJ

Ownership snapshot

Top shareholders of INTERPACE BIOSCIENCES, INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Douglas M. Singer
Disclosed value leader
Ampersand 2018 Limited Pa...
Comparable rows
1/9
Latest evidence
20 Aug 2026
13D/G 3/4/5 Lead comparable stake: 4.4% 8 rows are not safely comparable across share classes. 13D/G row: Douglas M. Singer Showing 1-8 of 9 holder rows.

Quick read

Douglas M. Singer leads the comparable SEC ownership view at 4.4%.

1 of 9 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Douglas M. Singer's linked filing trail.
Comparable ownership Top 1
Douglas M. Singer 4.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 9 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Douglas M. Singer
13D/G
4.4%
$264,252
195,742 shares
-$42,260 10 Jan 2025
Ampersand 2018 Limited Partnership
3/4/5
10%+ Owner
class O/S missing
$27,999,999
13,861,386 shares
20 Jan 2026
1315 Capital II, L.P.
3/4/5
10%+ Owner
class O/S missing
$19,000,000
9,405,941 shares
20 Jan 2026
Christopher McCarthy
3/4/5
CFO & COO
mixed-class rows
$94,518
877,818 shares
mixed-class rows
20 Aug 2026
Thomas W. Burnell
3/4/5
CEO, President & Chairman, Director
mixed-class rows
2,020,830 shares
mixed-class rows
20 Aug 2026
Vijay Aggarwal
3/4/5
Director
mixed-class rows
97,252 shares
mixed-class rows
20 Aug 2026
Fortunato R. Rocca
3/4/5
Director
class O/S missing
69,252 shares
20 Aug 2026
Joseph D. Keegan
3/4/5
Director
class O/S missing
69,252 shares
20 Aug 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 10 Sep 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-8 of 8 reporting-owner rows connected to INTERPACE BIOSCIENCES, INC.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
8
Largest Forms 3/4/5 holder
Ampersand 2018 Limited Partnership
Net 12M change
$0
Latest report
20 Aug 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Ampersand 2018 Limited Partnership 10%+ Owner $27,999,999 Mixed 20 Jan 2026
1315 Capital II, L.P. 10%+ Owner $19,000,000 Mixed 20 Jan 2026
Christopher McCarthy Cfo & Coo $94,518 Mixed 20 Aug 2026
Stephen J. Sullivan Director Mixed 20 Aug 2026
Joseph D. Keegan Director Mixed 20 Aug 2026
Fortunato R. Rocca Director Mixed 20 Aug 2026
Thomas W. Burnell CEO, President & Chairman, Director Mixed 20 Aug 2026
Vijay Aggarwal Director Mixed 20 Aug 2026

Recent insider transactions for INTERPACE BIOSCIENCES, INC.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Thomas W. Burnell IDXG Common Stock Tax liability -28.6% -581,718 1,455,927 20 Aug 2026 Direct
Thomas W. Burnell IDXG Common Stock Options Exercise 2774.7% 1,966,763 2,037,645 20 Aug 2026 Direct
Thomas W. Burnell IDXG Stock Option (right to buy) Award 554,018 554,018 20 Aug 2026 Direct
Thomas W. Burnell IDXG Restricted Stock Units Options Exercise -100% -1,966,763 0 20 Aug 2026 Direct
Thomas W. Burnell IDXG Restricted Stock Units Award 1,966,763 1,966,763 20 Aug 2026 Direct
Vijay Aggarwal IDXG Restricted Stock Units Award 69,252 69,252 20 Aug 2026 Direct
Fortunato R. Rocca IDXG Restricted Stock Units Award 69,252 69,252 20 Aug 2026 Direct
Joseph D. Keegan IDXG Restricted Stock Units Award 69,252 69,252 20 Aug 2026 Direct
Stephen J. Sullivan IDXG Restricted Stock Units Award 69,252 69,252 20 Aug 2026 Direct
Christopher McCarthy IDXG Common Stock Options Exercise 592% 277,009 323,800 20 Aug 2026 Direct
Christopher McCarthy IDXG Stock Option (right to buy) Award 277,009 277,009 20 Aug 2026 Direct
Christopher McCarthy IDXG Restricted Stock Units Options Exercise -50% -277,009 277,009 20 Aug 2026 Direct
Christopher McCarthy IDXG Restricted Stock Units Award 554,018 554,018 20 Aug 2026 Direct
1315 Capital II, L.P. IDXG Common Stock Conversion of derivative security 9,405,941 9,405,941 20 Jan 2026 Direct
1315 Capital II, L.P. IDXG Series C Convertible Preferred Stock Conversion of derivative security -100% -19,000 0 20 Jan 2026 Direct
Ampersand 2018 Limited Partnership IDXG Common Stock Conversion of derivative security 13,861,386 13,861,386 20 Jan 2026 Direct
Ampersand 2018 Limited Partnership IDXG Series C Convertible Preferred Stock Conversion of derivative security -100% -28,000 0 20 Jan 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .